SALZBURG BREAST CANCER TALK 10. – 11.02.2017
MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY
FRIDAY, 10th FEBRUARY
12:30 – 13:30
Come together and Lunch Buffet
13:30
Welcome and introduction
13:40 – 15:30 Immunogenicity
Chair: Richard Greil (Salzburg), Karen Willard-Gallo (Brussels)
13:40
Current evidence for immune checkpoint blockade in breast cancer
14:00
Is breast cancer an immunogenic tumor?
14:20
The importance of tumor infiltrating lymphocytes in breast cancer:
Is Godot finally arriving? 14:40
Panel discussion
15:30 – 16:00
Coffee break
16:00 – 17:30
16:00
16:30
17:00
New strategies and techniques
Chair: Fritz Aberger (Salzburg), Gabriel Rinnerthaler (Salzburg)
CAR-engineered natural killer cells targeting HER2*
Immunomodulatory antibodies beyond PD-1/PD-L1*
In vivo tracking of lymphocytes by PET*
Richard Greil (Salzburg)
Simon P. Gampenrieder (Salzburg)
Karen Willard-Gallo (Brussels)
Roberto Salgado (Brussels)
Winfried Wels (Frankfurt)
Andrea van Elsas (Oss)
Bernd Pichler (Tübingen)
18:00Dinner
SATURDAY, 11th FEBRUARY
08:30 – 10:00
08:30
09:00
09:30
10:00 – 10:30
From bedside to bench
Chair: Dirk Schadendorf (Essen), Simon P. Gampenrieder (Salzburg)
Principles of tailoring the immune system against cancer –
What can we learn from other entities*
Trial concepts in immunooncology*
Mouse models in immunooncology*
Coffee break
10:30 – 12:00
10:30
10:50
11:10
11:30
Combination strategies with checkpoint-inhibitors
Chair: Giuseppe Curigliano (Milan), Richard Greil (Salzburg)
Combination with chemotherapy
Combination with vaccination
Combination with radiotherapy
Panel discussion
12:00
Lunch Buffet
* Discussion after lecture
Dirk Schadendorf (Essen)
Gabriel Rinnerthaler (Salzburg)
Alexander Egle (Salzburg)
Giuseppe Curigliano (Milan)
Richard Greil (Salzburg)
Udo Gaipl (Erlangen)
The Pitter Event Center
Rainerstrasse 6 – 8
5020 Salzburg
www.imlauer.com
Free WLAN-Access:
CP event_open
Prof. Dr. Richard Greil
Head of the IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria
Prof. Dr. Winfried S. Wels
Georg-Speyer-Haus
Institute for Tumor Biology and
Experimental Therapy
Frankfurt am Main, Germany
Dr. Gabriel Rinnerthaler
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria
Dr. Simon P. Gampenrieder
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria
Dr. Andrea van Elsas
Chief Scientific Officer
Aduro Biotech Europe
Oss, the Netherlands
Priv.-Doz. Dr. Alexander Egle
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria
Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory
Institut Jules Bordet
Université Libre de Bruxelles
Brussels, Belgium
Dr. Roberto Salgado
Breast Cancer Translational Research
Laboratory, Department of Pathology, GZA
Institut Jules Bordet, Brussels
Antwerp, Belgium
Prof. Dr. Bernd Pichler
Director & Chair
Department of Preclinical Imaging
and Radiopharmacy
Eberhard Karls University of Tübingen
Tübingen, Germany
Prof. Dr. Dirk Schadendorf
Director & Chair, Department of Dermatology & Director, Comprehensive Cancer
Center (Westdeutsches Tumorzentrum)
University Hospital Essen
Essen, Germany
Giuseppe Curigliano MD PhD
New Drugs and Early Drug Development
for Innovative Therapies Division
European Institute of Oncology
Milan, Italy
Prof. Dr. Udo Gaipl
Head of Radiation Immunobiology
Universitätsklinikum Erlangen
Department of Radiation Oncology
Erlangen, Germany
Prof. Dr. Fritz Aberger
Molecular Cancer and Stem Cell Research
LabDepartment of Molecular Biology
University of Salzburg
Salzburg, Austria
Organ izati on:
R ich a rd G rei l
Gab r iel Ri nne rth al e r
Sim o n P. G a m p e n ried e r
Sal zbu rg Cance r R esea rch I nst itut e ( SCRI) w ith
Lab ora t or y o f I m m un ol o g i cal a nd Molecu lar Can ce r R esearch (SC RI-LIMC R)
ww w. li m c r. a t a nd
Cente r for Cl i n i cal Ca n ce r a nd I mmu n ology Trial s (SCR I - CCCIT )
ww w. ccc i t . at
ve
nt
Th
is
e
Kindly sup p or t ed by :
7 D has
FP been
po app
in rove
ts d fo
r
in coo p erat io n wi th th e
Can cer Cl ust e r Sal zbu rg | www. can ce rclu ste r-salzbu rg. at and AGMT gemei nnüt zi ge G mb H | www.agmt .a t